Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical and biotechnology company focused on developing effective, rapid-acting and convenient mental health treatments. The AtaiBeckley news feed on Stock Titan aggregates company announcements, press releases and regulatory disclosures so readers can follow how its clinical programs and corporate developments evolve over time.
News about AtaiBeckley frequently highlights progress across its pipeline of investigational therapies. This includes updates on BPL-003, a mebufotenin (5-MeO-DMT) benzoate nasal spray for treatment-resistant depression and alcohol use disorder; VLS-01, a DMT buccal film for treatment-resistant depression; and EMP-01, an oral R-MDMA formulation for social anxiety disorder. Company releases have covered Phase 2b and open-label extension data for BPL-003, enrollment and site expansion for VLS-01 trials, and exploratory Phase 2a work for EMP-01, as well as regulatory milestones such as FDA Breakthrough Therapy designation for BPL-003.
Investors and observers can also use the ATAI news page to follow corporate events, including the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited to form AtaiBeckley, the company’s redomiciliation to the United States as AtaiBeckley Inc., and its addition to the Nasdaq Biotechnology Index. Filings and press releases related to public offerings, grants from organizations such as the National Institute on Drug Abuse, and intellectual property developments like the U.S. patent granted for EMP-01 are also reflected in the news flow.
By reviewing AtaiBeckley news in one place, readers can track key clinical milestones, financing activities, regulatory designations and strategic transactions that shape the company’s efforts in mental health therapeutics. The ATAI news page can be revisited regularly to see new company communications and related market updates as they are released.
atai Life Sciences reported a robust cash position of $312M as of June 30, 2022, boosted by a non-dilutive debt facility of up to $175M, extending its financial runway into 2025. The company has achieved several key milestones in its R&D pipeline, including the completion of a clinical phase study for PCN-101, database lock for GRX-917, and initiation of VLS-01. Expected clinical data readouts from eight programs are anticipated within the next 12 months, signaling potential significant developments in mental health treatments.
atai Life Sciences N.V. announced a term loan facility of up to $175 million with Hercules Capital to enhance its financial position in developing novel mental health treatments. This non-dilutive financing, combined with existing cash of $312 million, provides access to $487 million for advancing its drug pipeline. The funding structure includes flexible draw options and a 10.05% interest rate, maturing in 48 months. The CEO emphasized the strategic flexibility this provides for addressing unmet needs in neuropsychiatry.
atai Life Sciences, a clinical-stage biopharmaceutical company, will announce its second quarter 2022 financial results on August 15, 2022. The firm is focused on innovating treatments for mental health disorders, including depression and anxiety. A video interview with management will be available at 8:30 a.m. ET on the same day, with the recording to be accessible on their website. Founded in 2018, atai aims to accelerate drug development through a unique business model that integrates funding and regulatory expertise to tackle mental health challenges.
Kures Therapeutics, a subsidiary of atai Life Sciences (Nasdaq: ATAI), announced the appointment of Dr. Chad Beyer as CEO effective July 1, 2022. Dr. Beyer brings over 25 years of experience in CNS and neurological medication development. He has led numerous IND submissions and contributed to two blockbuster drugs. Outgoing CEO Dr. Srinivas Rao will support Kures from atai Life Sciences. Kures is focused on developing KUR-101, an innovative treatment for opioid use disorder, showing promising preclinical results without significant side effects.
atai Life Sciences N.V. (Nasdaq: ATAI) announced the appointment of Stephen Bardin as CFO Designate starting June 27, 2022. Bardin, previously Senior VP of Finance at BridgeBio Pharma, brings extensive financial expertise, including raising over USD 2B. Current CFO Greg Weaver will transition to a strategic advisory role by March 31, 2023. With a strong cash balance of USD 335M as of March 31, 2022, the company aims to advance innovative mental health treatments. CEO Florian Brand expressed confidence in Bardin's fit for the team, emphasizing the need for transformative solutions in mental health.
atai Life Sciences (Nasdaq: ATAI), a biopharmaceutical company focused on mental health treatments, will participate in key healthcare conferences this June. The BIO International Conference will feature a company presentation on June 16 from 2:45 PM to 3:15 PM ET. Following this, the H.C. Wainwright 1st Annual Mental Health Conference is scheduled for June 27 at 12:00 PM ET. Both events aim to highlight atai's innovative approaches to mental health disorders. Archived webcasts will be available on atai's website for further insights.
atai Life Sciences reported significant progress in its clinical pipeline for Q1 2022, including dosing the first subject in the Phase 1 KUR-101 trial and launching its drug discovery engine, Invyxis. With a cash position of $335 million, the company is well-funded to continue its initiatives. Key milestones anticipated for 2022 include data from the Phase 2 PCN-101 study for treatment-resistant depression and more Phase 1 and 2 trial initiations. However, R&D expenses surged to $15.5 million, contributing to a net loss of $36.9 million this quarter.
atai Life Sciences (Nasdaq: ATAI) is a clinical-stage biopharmaceutical company focused on addressing mental health disorders. The firm will announce its Q1 2022 financial results and business updates on May 16, 2022. A video interview with management will be available at 8:30 a.m. (ET) for investors to gain insights into the company's performance. Founded in 2018, atai combines funding, technology, and expertise to develop innovative therapeutics, including psychedelic therapies, aimed at transforming mental health treatment.
atai Life Sciences N.V. (Nasdaq: ATAI) will announce its first-quarter 2022 financial results on its investor relations website. A video interview featuring CEO Florian Brand, CSO Srinivas Rao, and CFO Greg Weaver is set for May 9, 2022, at 8:30 A.M. Eastern Time. atai focuses on transforming mental health treatment through innovative therapeutics, particularly in the areas of depression, anxiety, and addiction. Founded in 2018, it aims to address unmet needs in mental health care.
atai Life Sciences (Nasdaq: ATAI) will present at the Benzinga Psychedelics Conference on April 19, 2022, from 1:10 p.m. to 1:40 p.m. ET. This event will take place both in person and virtually. Investors can access the presentation via a provided conference link.
Founded in 2018, atai focuses on innovative therapies for mental health disorders including depression and anxiety. The company's goal is to heal mental health issues globally, utilizing a unique business model that integrates funding, technology, and expertise.
FAQ
What is the current stock price of Atai Beckley (ATAI)?
What is the market cap of Atai Beckley (ATAI)?
